Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Arquer Diagnostics Ltd.. (3/1/17). "Press Release: Arquer Diagnostics Awarded Funding Under Innovate UK’s Biocatalyst Programme". Sunderland.

Region Region United Kingdom (GB)
Organisations Organisation Arquer Diagnostics Ltd.
  Organisation 2 Innovate UK
  Group United Kingdom (GB) (govt)
Products Product Mcm5-ELISA test (UroSens / Arquer Diagnostics)
  Product 2 business development (state/region)
Person Person Whittley, Nadia (Arquer Diagnostics 201612– CEO before Tefen Management Consulting + Alium Medical + Allergan)

Funding will be used to prepare for international clinical study to evaluate the Company’s ELISA-based urine test for prostate cancer

Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ELISA-based urine test for bladder cancer, today announced that it has been awarded £70,000 funding under Innovate UK’s Biocatalyst programme, to be awarded over a 12 month period, starting 1st March 2017. The funding will be used to support preparations for an international clinical study to evaluate Arquer’s MCM5 ELISA-based non-invasive test for prostate cancer, as the Company expands the application of its technology into a wider range of cancers.

Arquer’s diagnostic test, the MCM5-ELISA, detects the presence of minichromosome maintenance (MCM) protein, a marker for the presence of dividing cancer cells, to accurately diagnose cancer. MCM proteins are excellent biomarkers, being directly involved in cell replication, and are shed into urine by both prostate and bladder tumours. The funding follows the recent appointment of Nadia Whittley as CEO.

The study will utilise urine and semen samples from up to 100 patients, in order to inform the design of a wider clinical trial expected to commence in late 2017.

Commenting on the funding, Stuart McCracken, PhD, Consultant Urologist Sunderland Royal Hospital, UK, and UK Clinical Investigator for the study said: “There is an urgent need to find, and robustly validate, a novel cancer biomarker of prostate cancer. Studies such as this provide evidence that may support a change in the diagnostic pathway and start to allow reductions in expensive and unnecessary prostate biopsies which are very unpopular with patients and are a major financial burden to healthcare providers.”

Nadia Whittley, CEO, Arquer Diagnostics, commented: “We are delighted that Innovate UK has identified the potential opportunity provided by our diagnostic test, particularly as we move forward to commercialise our MCM5 ELISA diagnostic test. The MCM5 ELISA is expected to significantly reduce the number of patients undergoing invasive and costly techniques such as cystoscopy and biopsy, because it offers highly accurate diagnostic results from small amounts of body fluid.”

Posted on 1st March 2017

Contact Us
North East Business and Innovation Centre, Wearfield, Enterprise Park East, Sunderland, SR5 2TA
Tel: +44 (0) 191 516 6765

Record changed: 2023-06-05


Picture Berlin Partner Top News Healthtech Company Mika 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top